APEC1621A, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 sub-protocol of LOXO-101 (larotrectinib) in patients with tumors harboring NTRK fusions.

About This Study

This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.